Australia TGA ARTG recordOptipac® Refobacin® Bone Cement R - Orthopaedic cement, medicated
Australia TGA ARTG Registered Device · Zimmer Biomet Pty Ltd · Biomet France · Class III · Started May 30, 2024
Good Name: Zimmer Biomet Pty Ltd - Optipac® Refobacin® Bone Cement R - Orthopaedic cement, medicated
- Risk Class
- Class III
- Product Type
- Procedure Pack
- ARTG Category
- General
- Start Date
- May 30, 2024
- Effective Date
- May 30, 2024
- Name
- Biomet France
- Country
- France
- Address
- Plateau de Lautagne, Valence, 26000
Optipac® Refobacin® Bone Cement R is indicated to be used for stable anchoring of suitable joint prostheses to the bone, in hip and knee primary arthroplasty operations, also in case an infection with gentamicin-sensitive strains is a potential risk.
Access comprehensive regulatory information for Optipac® Refobacin® Bone Cement R - Orthopaedic cement, medicated in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class III is sponsored by Zimmer Biomet Pty Ltd, manufactured by Biomet France in France. The device registration started on May 30, 2024.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.